drugset / Trial / NCT04638309
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.
Timeline
- Start
- 2021-09-20
- Primary completion
- 2022-04-25
- Completion
- 2022-04-25
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APR-548 | Unknown | — | Oral |
| Subject | Azacitidine | Other / unclassified | — | — |